Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00035024.xml
Download PDF
CC BY 4.0 · Thromb Haemost
DOI: 10.1055/a-2595-1811
DOI: 10.1055/a-2595-1811
Review Article
Consensus on the Management of the Clinical Challenges of Venous Thromboembolism in Special Situations
Abstract
Venous thromboembolism (VTE) can present different challenging situations for which high-quality evidence to guide optimal preventive and therapeutic management is lacking and for which clinical practice guidelines have not established solid recommendations. The aim of this article is to achieve consensus on a proposal of action for the clinical management of complex, clinically relevant situations with a low level of evidence which generate great uncertainty—the duration of VTE treatment and the role of thrombus recanalization, the prevention of VTE within the context of pregnancy, management of anticoagulant treatment in patients with VTE and special characteristics, such as renal insufficiency and obesity, the therapeutic management of pluripathological and polymedicated older patients with VTE, and finally, primary ambulatory thromboembolic prevention in cancer patients. This consensus article arose from a collaboration of experts in VTE from different medical specialties.
Publication History
Received: 03 July 2024
Accepted: 16 December 2024
Article published online:
13 May 2025
© 2025. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)
Georg Thieme Verlag KG
Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany
-
References
- 1 Ageno W, Haas S, Weitz JI. et al; GARFIELD-VTE investigators. Characteristics and management of patients with venous thromboembolism: the GARFIELD-VTE registry. Thromb Haemost 2019; 119 (02) 319-327
- 2 Martens KL, Dekker SE, Crowe M, DeLoughery TG, Shatzel JJ. Challenging clinical scenarios for therapeutic anticoagulation: a practical approach. Thromb Res 2022; 218: 72-82
- 3 Dykewicz CA. Centers for Disease Control and Prevention (U.S.), Infectious Diseases Society of America, American Society of Blood and Marrow Transplantation. Summary of the guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. Clin Infect Dis 2001; 33 (02) 139-144
- 4 Kakkos SK, Gohel M, Baekgaard N. et al; Esvs Guidelines Committee. Editor's choice—European Society for Vascular Surgery (ESVS) 2021 clinical practice guidelines on the management of venous thrombosis. Eur J Vasc Endovasc Surg 2021; 61 (01) 9-82
- 5 Weitz JI, Prandoni P, Verhamme P. Anticoagulation for patients with venous thromboembolism: when is extended treatment required?. TH Open 2020; 4 (04) e446-e456
- 6 Mazzolai L, Ageno W, Alatri A. et al. Second consensus document on diagnosis and management of acute deep vein thrombosis: updated document elaborated by the ESC Working Group on aorta and peripheral vascular diseases and the ESC Working Group on pulmonary circulation and right ventricular function. Eur J Prev Cardiol 2022; 29 (08) 1248-1263
- 7 Daskalopoulos ME, Daskalopoulou SS, Tzortzis E. et al. Long-term treatment of deep venous thrombosis with a low molecular weight heparin (tinzaparin): a prospective randomized trial. Eur J Vasc Endovasc Surg 2005; 29 (06) 638-650
- 8 Stevens SM, Woller SC, Kreuziger LB. et al. Antithrombotic therapy for VTE disease: second update of the CHEST guideline and expert panel report. Chest 2021; 160 (06) e545-e608 . Erratum in: Chest. 2022 Jul;162(1):269. PMID: 34352278
- 9 Hull RD, Liang J, Townshend G. Long-term low-molecular-weight heparin and the post-thrombotic syndrome: a systematic review. Am J Med 2011; 124 (08) 756-765
- 10 Hull RD, Pineo GF, Brant R. et al; LITE Trial Investigators. Home therapy of venous thrombosis with long-term LMWH versus usual care: patient satisfaction and post-thrombotic syndrome. Am J Med 2009; 122 (08) 762-769.e3
- 11 Carrier M, Rodger MA, Wells PS, Righini M, LE Gal G. Residual vein obstruction to predict the risk of recurrent venous thromboembolism in patients with deep vein thrombosis: a systematic review and meta-analysis. J Thromb Haemost 2011; 9 (06) 1119-1125
- 12 Cosmi B, Legnani C, Iorio A. et al; PROLONG Investigators (on behalf of FCSA, Italian Federation of Anticoagulation Clinics). Residual venous obstruction, alone and in combination with D-dimer, as a risk factor for recurrence after anticoagulation withdrawal following a first idiopathic deep vein thrombosis in the prolong study. Eur J Vasc Endovasc Surg 2010; 39 (03) 356-365
- 13 Donadini MP, Ageno W, Antonucci E. et al. Prognostic significance of residual venous obstruction in patients with treated unprovoked deep vein thrombosis: a patient-level meta-analysis. Thromb Haemost 2014; 111 (01) 172-179
- 14 Iding AFJ, Kremers BMM, Pallares Robles A, Ten Cate H, Ten Cate-Hoek AJ. Residual venous obstruction as an indicator of clinical outcomes following deep vein thrombosis: a management study. Thromb Haemost 2023; 123 (08) 763-772
- 15 LE Gal G, Carrier M, Kovacs MJ. et al. Residual vein obstruction as a predictor for recurrent thromboembolic events after a first unprovoked episode: data from the REVERSE cohort study. J Thromb Haemost 2011; 9 (06) 1126-1132
- 16 Napolitano M, Saccullo G, Raso S. et al. Cancer-associated deep vein thrombosis: the role of residual vein thrombosis for assessing the duration of low molecular weight heparin (the EXTENDED Cancer-DACUS). Blood 2014; 124 (21) 4277
- 17 Lindqvist PG, Westerlund E, Hellgren M. Swedish obstetric thromboprophylaxis guideline: background and update. J Obstet Gynaecol 2023; 43 (02) 2241527
- 18 Pabinger I, Grafenhofer H, Kyrle PA. et al. Temporary increase in the risk for recurrence during pregnancy in women with a history of venous thromboembolism. Blood 2002; 100 (03) 1060-1062
- 19 Bates SM, Rajasekhar A, Middeldorp S. et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: venous thromboembolism in the context of pregnancy. Blood Adv 2018; 2 (22) 3317-3359
- 20 Bates SM, Greer IA, Middeldorp S, Veenstra DL, Prabulos AM, Vandvik PO. VTE, thrombophilia, antithrombotic therapy, and pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed. American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141 (2 Suppl): e691S-e736S
- 21 Royal College of Obstetricians and Gynaecologists. Reducing the Risk of Venous Thromboembolism during Pregnancy and the Puerperium. Green-top Guideline No. 37a. 2015 ; available at: https://www.rcog.org.uk/media/qejfhcaj/gtg-37a.pdf
- 22 Hart C, Bauersachs R, Scholz U. et al. Prevention of venous thromboembolism during pregnancy and the puerperium with a special focus on women with hereditary thrombophilia or prior VTE. Position paper of the working group in women's health of the Society of Thrombosis and Haemostasis (GTH). Hamostaseologie 2020; 40 (05) 572-590
- 23 American College of Obstetricians and Gynecologists' Committee on Practice Bulletins—Obstetrics. ACOG Practice Bulletin No. 196: thromboembolism in pregnancy. Obstet Gynecol 2018; 132 (01) e1-e17
- 24 Chan WS, Rey E, Kent NE. et al; VTE in Pregnancy Guideline Working Group, Society of Obstetricians and Gynecologists of Canada. Venous thromboembolism and antithrombotic therapy in pregnancy. J Obstet Gynaecol Can 2014; 36 (06) 527-553
- 25 Bistervels IM, Buchmüller A, Wiegers HMG. et al; Highlow Block writing committee, Highlow Investigators. Intermediate-dose versus low-dose low-molecular-weight heparin in pregnant and post-partum women with a history of venous thromboembolism (Highlow study): an open-label, multicentre, randomised, controlled trial. Lancet 2022; 400 (10365): 1777-1787
- 26 Ribic C, Crowther M. Thrombosis and anticoagulation in the setting of renal or liver disease. Hematology (Am Soc Hematol Educ Program) 2016; 2016 (01) 188-195
- 27 Wattanakit K, Cushman M. Chronic kidney disease and venous thromboembolism: epidemiology and mechanisms. Curr Opin Pulm Med 2009; 15 (05) 408-412
- 28 Messi M, Beneyto Afonso C, Stalder O. et al. Long-term clinical outcomes in older patients with acute venous thromboembolism who have renal impairment. Thromb Res 2022; 218: 64-71
- 29 Königsbrügge O, Ay C. Atrial fibrillation in patients with end-stage renal disease on hemodialysis: magnitude of the problem and new approach to oral anticoagulation. Res Pract Thromb Haemost 2019; 3 (04) 578-588
- 30 Witt DM, Nieuwlaat R, Clark NP. et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: optimal management of anticoagulation therapy. Blood Adv 2018; 2 (22) 3257-3291
- 31 Konstantinides SV, Meyer G, Becattini C. et al; ESC Scientific Document Group. 2019 ESC guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Eur Heart J 2020; 41 (04) 543-603
- 32 Pradaxa® Summary of Product Characteristics. Accessed in March 2024 at: https://www.ema.europa.eu/en/documents/product-information/pradaxa-epar-product-information_en.pdf
- 33 Xarelto® Summary of Product Characteristics. Accessed in January 2024 at: https://www.ema.europa.eu/en/documents/product-information/xarelto-epar-product-information_en.pdf
- 34 Eliquis® Summary of Product Characteristics. Accessed in March 2024 at: https://www.ema.europa.eu/en/documents/product-information/eliquis-epar-product-information_en.pdf
- 35 Lixiana® Summary of Product Characteristics. Accessed in March 2024 at: https://www.ema.europa.eu/en/documents/product-information/lixiana-epar-product-information_en.pdf
- 36 Amerali M, Politou M. Tinzaparin—a review of its molecular profile, pharmacology, special properties, and clinical uses. Eur J Clin Pharmacol 2022; 78 (10) 1555-1565
- 37 Helfer H, Siguret V, Mahé I. Tinzaparin sodium pharmacokinetics in patients with chronic kidney disease: practical implications. Am J Cardiovasc Drugs 2020; 20 (03) 223-228
- 38 Innohep® Summary of Product Characteristics. Accessed in March 2024 at: https://cima.aemps.es/cima/pdfs/ft/77153/FT_77153.pdf
- 39 Inhixa® Summary of Product Characteristics. Accessed in March 2024 at: https://www.ema.europa.eu/en/medicines/human/EPAR/inhixa#ema-inpage-item-product-info
- 40 Hibor® Summary of Product Characteristics. Accessed in March 2024 at: https://cima.aemps.es/cima/pdfs/es/ft/64166/64166_ft.pdf
- 41 Fragmin® Summary of Product Characteristics. Accessed in March 2024 at: https://cima.aemps.es/cima/dochtml/p/62155/P_62155.html
- 42 Fraxiparina® Summary of Product Characteristics. Accessed in March 2024 at: https://cima.aemps.es/cima/dochtml/ft/58983/FT_58983.html
- 43 Chokesuwattanaskul R, Thongprayoon C, Tanawuttiwat T, Kaewput W, Pachariyanon P, Cheungpasitporn W. Safety and efficacy of apixaban versus warfarin in patients with end stage renal disease: meta-analysis. Pacing Clin Electrophysiol 2018; 41 (06) 627-634
- 44 Sintrom® Summary of Product Characteristics. Accessed in March 2024 at: https://cima.aemps.es/cima/dochtml/ft/25670/FT_25670.html
- 45 Egan G, Ensom MH. Measuring anti-factor Xa activity to monitor low-molecular-weight heparin in obesity: a critical review. Can J Hosp Pharm 2015; 68 (01) 33-47
- 46 Muñoz Martín AJ, Gallardo Díaz E, García Escobar I. et al. SEOM clinical guideline of venous thromboembolism (VTE) and cancer (2019). Clin Transl Oncol 2020; 22 (02) 171-186
- 47 Pfrepper C, Metze M, Weise M. et al. Body weight adapted tinzaparin treatment in patients with obesity. Thromb Res 2022; 214: 65-67
- 48 Maclachlan KH, Stevens HP, Tran HA, Chunilal SD. Weight-based enoxaparin for venous thromboembolism in obesity gives similar anti-Xa levels to patients <100 kg, with no increase in major bleeding. Semin Thromb Hemost 2019; 45 (01) 94-99
- 49 Ortel TL, Neumann I, Ageno W. et al. American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism. Blood Adv 2020; 4 (19) 4693-4738
- 50 Falanga A, Ay C, Di Nisio M. et al; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Venous thromboembolism in cancer patients: ESMO Clinical Practice Guideline. Ann Oncol 2023; 34 (05) 452-467
- 51 Garcia D, Baglin T, Weitz J, Samama M. Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141 (02) 24-43
- 52 Kearon C, Akl EA, Ornelas J. et al. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. [published correction appears in Chest. 2016 Oct;150(4):988] Chest 2016; 149 (02) 315-352
- 53 Martin KA, Beyer-Westendorf J, Davidson BL, Huisman MV, Sandset PM, Moll S. Use of direct oral anticoagulants in patients with obesity for treatment and prevention of venous thromboembolism: updated communication from the ISTH SSC Subcommittee on Control of Anticoagulation. J Thromb Haemost 2021; 19 (08) 1874-1882
- 54 Stein PD, Hull RD, Kayali F, Ghali WA, Alshab AK, Olson RE. Venous thromboembolism according to age: the impact of an aging population. Arch Intern Med 2004; 164 (20) 2260-2265
- 55 Elalamy I, Hanon O, Deray G, Launay-Vacher V. Anticoagulants in frail patients. Seven situations at risk. J Med Vasc 2018; 43 (05) 302-309
- 56 Sanghai S, Wong C, Wang Z. et al. Rates of potentially inappropriate dosing of direct-acting oral anticoagulants and associations with geriatric conditions among older patients with atrial fibrillation: the SAGE-AF study. J Am Heart Assoc 2020; 9 (06) e014108
- 57 Ellis G, Sevdalis N. Understanding and improving multidisciplinary team working in geriatric medicine. Age Ageing 2019; 48 (04) 498-505
- 58 Merli GJ. Treatment of deep venous thrombosis and pulmonary embolism with low molecular weight heparin in the geriatric patient population. Clin Geriatr Med 2001; 17 (01) 93-106
- 59 Mismetti P, Laporte-Simitsidis S, Navarro C. et al. Aging and venous thromboembolism influence the pharmacodynamics of the anti-factor Xa and anti-thrombin activities of a low molecular weight heparin (nadroparin). Thromb Haemost 1998; 79 (06) 1162-1165
- 60 Pautas E, Gouin I, Bellot O, Andreux JP, Siguret V. Safety profile of tinzaparin administered once daily at a standard curative dose in two hundred very elderly patients. Drug Saf 2002; 25 (10) 725-733
- 61 Geldhof V, Vandenbriele C, Verhamme P, Vanassche T. Venous thromboembolism in the elderly: efficacy and safety of non-VKA oral anticoagulants. Thromb J 2014; 12: 21
- 62 Prins MH, Lensing AW, Bauersachs R. et al; EINSTEIN Investigators. Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies. Thromb J 2013; 11 (01) 21
- 63 Vanassche T, Verhamme P, Wells PS. et al. Impact of age, comorbidity, and polypharmacy on the efficacy and safety of edoxaban for the treatment of venous thromboembolism: an analysis of the randomized, double-blind Hokusai-VTE trial. Thromb Res 2018; 162: 7-14
- 64 López-Jiménez L, Montero M, González-Fajardo JA. et al; RIETE Investigators. Venous thromboembolism in very elderly patients: findings from a prospective registry (RIETE). Haematologica 2006; 91 (08) 1046-1051
- 65 Iñurrieta A, Pedrajas JM, Núñez MJ. et al; RIETE Investigators. Outcomes beyond the third month of anticoagulation in patients aged >75 years with a first episode of unprovoked venous thromboembolism. TH Open 2018; 2 (04) e428-e436
- 66 Drăgan A, Drăgan AS. Novel insights in venous thromboembolism risk assessment methods in ambulatory cancer patients: from the guidelines to clinical practice. Cancers (Basel) 2024; 16 (02) 458
- 67 Mulder FI, Horváth-Puhó E, van Es N. et al. Venous thromboembolism in cancer patients: a population-based cohort study. Blood 2021; 137 (14) 1959-1969
- 68 Khorana AA, Dalal M, Tangirala K, Miao R. Higher incidence of venous thromboembolism in the outpatient versus the inpatient setting among US cancer patients. Blood 2011; 118 (21) 674
- 69 Muñoz Martín AJ, García Alfonso P, Rupérez Blanco AB, Pérez Ramírez S, Blanco Codesido M, Martín Jiménez M. Incidence of venous thromboembolism (VTE) in ambulatory pancreatic cancer patients receiving chemotherapy and analysis of Khorana's predictive model. Clin Transl Oncol 2014; 16 (10) 927-930
- 70 Chiari R, Ricciuti B, Landi L. et al. ROS1-rearranged non-small-cell lung cancer is associated with a high rate of venous thromboembolism: analysis from a phase II, prospective, multicenter, two-arms trial (METROS). Clin Lung Cancer 2020; 21 (01) 15-20
- 71 Zer A, Moskovitz M, Hwang DM. et al. ALK-rearranged non-small-cell lung cancer is associated with a high rate of venous thromboembolism. Clin Lung Cancer 2017; 18 (02) 156-161
- 72 Zugazagoitia J, Biosca M, Oliveira J. et al. Incidence, predictors and prognostic significance of thromboembolic disease in patients with advanced ALK-rearranged non-small cell lung cancer. Eur Respir J 2018; 51 (05) 1702431
- 73 Li A, La J, May SB. et al. Derivation and validation of a clinical risk assessment model for cancer-associated thrombosis in two unique US health care systems. J Clin Oncol 2023; 41 (16) 2926-2938
- 74 Elalamy I, Cohen-Solal A, Hanon O, Mirabel M, Mismetti P, Spano JP. Primary prevention of cancer-associated venous thrombosis: rationale and challenges in clinical practice. Curr Res Transl Med 2023; 71 (03) 103405
- 75 Pabinger I, van Es N, Heinze G. et al. A clinical prediction model for cancer-associated venous thromboembolism: a development and validation study in two independent prospective cohorts. Lancet Haematol 2018; 5 (07) e289-e298
- 76 Muñoz A, Ay C, Grilz E. et al. A clinical-genetic risk score for predicting cancer-associated venous thromboembolism: a development and validation study involving two independent prospective cohorts. J Clin Oncol 2023; 41 (16) 2911-2925
- 77 Key NS, Khorana AA, Kuderer NM. et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO guideline update. J Clin Oncol 2023; 41 (16) 3063-3071
- 78 Lyman GH, Carrier M, Ay C. et al. American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer. Blood Adv 2021; 5 (04) 927-974
- 79 Farge D, Frere C, Connors JM. et al; International Initiative on Thrombosis and Cancer (ITAC) advisory panel. 2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19. Lancet Oncol 2022; 23 (07) e334-e347
- 80 National Comprehensive Cancer Network. NCCN guideline on cancer-associated venous thromboembolic disease. Version 2. 2023. Accessed March 25, 2023 at: https://www.nccn.org/guidelines/guidelines-detail?category=3&id=1423
- 81 Bosch FTM, Mulder FI, Kamphuisen PW. et al. Primary thromboprophylaxis in ambulatory cancer patients with a high Khorana score: a systematic review and meta-analysis. Blood Adv 2020; 4 (20) 5215-5225
- 82 Tun NM, Guevara E, Oo TH. Benefit and risk of primary thromboprophylaxis in ambulatory patients with advanced pancreatic cancer receiving chemotherapy: a systematic review and meta-analysis of randomized controlled trials. Blood Coagul Fibrinolysis 2016; 27 (03) 270-274
- 83 Becattini C, Verso M, Muňoz A, Agnelli G. Updated meta-analysis on prevention of venous thromboembolism in ambulatory cancer patients. Haematologica 2020; 105 (03) 838-848
- 84 Frere C, Crichi B, Bournet B. et al. Primary thromboprophylaxis in ambulatory pancreatic cancer patients receiving chemotherapy: a systematic review and meta-analysis of randomized controlled trials. Cancers (Basel) 2020; 12 (08) 2028